It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
originally posted by: zandra
a reply to: Brotherman
Sorry it was all I could find. But it is not about the strange website I referred to but about an article in a very respected magazine. All peer reviewed. And the problem I have with the thought that ADE is becoming a frigthening possibility.
All I can say that is that there were more sites that had a link to the article. Problem: I can't find the sites anymore.
Our results revealed that antibodies mediating ADE of SARS-CoV-2 infection were not the result of pre-existing cross-reactive antibodies from other coronavirus infection34 374, but were generated de novo following infection with SARS-CoV-2. First, the plasma from COVID-19 patients did not significantly promote the enhancement of SARS-CoV coronavirus infection. Second, pre-incubation with SARS-CoV RBD did not block the enhancement of virus infection by either plasma or monoclonal antibody 7F3. Third, mAb 7F3, which promotes the enhancement of virus infection, specifically binds to
RBD of SARS-COV-2 virus, but no other coronaviruses. These results also suggest that ADE may be more likely to occur at later time points after recovery from COVID-19 when the concentration of neutralizing antibodies elicited by the primary SARS-CoV-2 infection have waned to suboptimal neutralizing level.
originally posted by: Sthrndream
www.medpagetoday.com...
Newer Vaccines Are Safer
Despite hesitancy about the relative newness of mRNA and adenoviral vector vaccines, these vaccines, in fact, have better safety profiles in terms of ADE than older types of vaccines, according to Bloom.
"The bottom line is that not only is the new technology faster to respond to a new viral pandemic, but so much safer and much more clearly scientifically designed," he said. "The S protein vaccines are so much cleaner, so much more carefully defined, and so much lower risk. All you're seeing is one protein from that virus. So the chances for ADE are much slimmer than with any of the older ways for making virus vaccines."
Transgenic Aedes aegypti Mosquitoes Transfer Genes into a Natural Population
Download PDF
Article
Open Access
Published: 10 September 2019
Transgenic Aedes aegypti Mosquitoes Transfer Genes into a Natural Population
Benjamin R. Evans, Panayiota Kotsakiozi, Andre Luis Costa-da-Silva, Rafaella Sayuri Ioshino, Luiza Garziera, Michele C. Pedrosa, Aldo Malavasi, Jair F. Virginio, Margareth L. Capurro & Jeffrey R. Powell
Scientific Reports volume 9, Article number: 13047 (2019) Cite this article
116k Accesses
38 Citations
2285 Altmetric
Metricsdetails
14 May 2020 Editor's Note: an editorial Expression of Concern on this article has now been published www.nature.com...
An Addendum to this article was published on 24 March 2020
This article has been updated
Abstract
In an attempt to control the mosquito-borne diseases yellow fever, dengue, chikungunya, and Zika fevers, a strain of transgenically modified Aedes aegypti mosquitoes containing a dominant lethal gene has been developed by a commercial company, Oxitec Ltd. If lethality is complete, releasing this strain should only reduce population size and not affect the genetics of the target populations. Approximately 450 thousand males of this strain were released each week for 27 months in Jacobina, Bahia, Brazil. We genotyped the release strain and the target Jacobina population before releases began for >21,000 single nucleotide polymorphisms (SNPs). Genetic sampling from the target population six, 12, and 27–30 months after releases commenced provides clear evidence that portions of the transgenic strain genome have been incorporated into the target population. Evidently, rare viable hybrid offspring between the release strain and the Jacobina population are sufficiently robust to be able to reproduce in nature. The release strain was developed using a strain originally from Cuba, then outcrossed to a Mexican population. Thus, Jacobina Ae. aegypti are now a mix of three populations. It is unclear how this may affect disease transmission or affect other efforts to control these dangerous vectors. These results highlight the importance of having in place a genetic monitoring program during such releases to detect un-anticipated outcomes.
originally posted by: Sthrndream
www.medpagetoday.com...
Newer Vaccines Are Safer
Despite hesitancy about the relative newness of mRNA and adenoviral vector vaccines, these vaccines, in fact, have better safety profiles in terms of ADE than older types of vaccines, according to Bloom.
"The bottom line is that not only is the new technology faster to respond to a new viral pandemic, but so much safer and much more clearly scientifically designed," he said. "The S protein vaccines are so much cleaner, so much more carefully defined, and so much lower risk. All you're seeing is one protein from that virus. So the chances for ADE are much slimmer than with any of the older ways for making virus vaccines."